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ORIGINAL ARTICLE
A Phase 1B, randomized, double blind, placebo controlled,
multiple-dose escalation study of NSI-189 phosphate, a
neurogenic compound, in depressed patients
M Fava1,2, K Johe3, L Ereshefsky4, LG Gertsik5, BA English4, JA Bilello6, LM Thurmond6, J Johnstone7, BC Dickerson8, N Makris8,
BB Hoeppner1,2, M Flynn1, D Mischoulon1,2, G Kinrys1,2 and MP Freeman1,2
We wanted to examine tolerability and efﬁcacy of NSI-189, a benzylpiperizine-aminiopyridine neurogenic compound for treating
major depressive disorder (MDD). This was a Phase 1B, double blind, randomized, placebo controlled, multiple-dose study with
three cohorts. The ﬁrst cohort received 40mg q.d. (n= 6) or placebo (n= 2), the second cohort 40 mg b.i.d. (n= 6) or placebo (n= 2),
and the third cohort 40mg t.i.d. (n= 6) or placebo (n= 2). Twenty-four patients with MDD were recruited, with the diagnosis and
severity conﬁrmed through remote interviews. Eligible patients received NSI-189 or placebo for 28 days in an inpatient setting with
assessments for safety, pharmacokinetics (PK) and efﬁcacy. Outpatient follow-up visits were conducted until day 84 (±3). NSI-189
was relatively well tolerated at all doses, with no serious adverse effects. NSI-189 area under the curve increased in a dose-related
and nearly proportional manner across the three cohorts, with a half-life of 17.4–20.5 h. The exploratory efﬁcacy measurements,
including Symptoms Of Depression Questionnaire (SDQ), Montgomery-Asberg Depression Scale (MADRS), Clinical Global
Impressions—Improvement (CGI-I), and The Massachusetts General Hospital (MGH) Cognitive and Physical Functioning
Questionnaire (CPFQ) showed a promising reduction in depressive and cognitive symptoms across all measures for NSI-189, with
signiﬁcant improvement in the SDQ and CPFQ, and a medium to large effect size for all measures. These improvements persisted
during the follow-up phase. In summary, NSI-189 shows potential as a treatment for MDD in an early phase study. The main
limitation of this preliminary study was the small sample size of each cohort.
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INTRODUCTION
Despite the number of pharmacologic agents on the market for
the treatment of depression, novel antidepressants with efﬁcacy
and tolerability are still in much need. Only approximately
one-third of patients with major depressive disorder (MDD)
achieve full remission of symptoms with currently available
antidepressants.1–4 Currently available antidepressants generally
share a mechanism of action focused on the monoamine
neurotransmitter system, suggesting that the most robust
potential advances in the ﬁeld may be most achievable by the
utilization of mechanisms of action different from those of
currently available medications.5 Importantly, currently available
antidepressants are associated with adverse effects that may
negatively impact treatment adherence, such as gastrointestinal
symptoms, agitation, sleep and weight changes, and sexual
dysfunction.6
Neurogenesis in the hippocampal formation has been
demonstrated throughout the lifetime of multiple species including
humans.7 Treatment with antidepressant drugs increases
hippocampal neurogenesis, and it has been hypothesized that
increasing adult hippocampal neurogenesis may be a new drug
target or mechanism for future antidepressant drugs.7,8 Therefore,
an accumulating body of evidence strongly supports the
hypothesis that a platform of pre-clinical neurogenesis paired
with conﬁrmatory behavioral assays may be useful as a drug
discovery strategy.
NSI-189, a benzylpiperizine-aminiopyridine, is a novel chemical
entity that stimulates neurogenesis of human hippocampus-derived
neural stem cells in vitro and stimulates neurogenesis in mouse
hippocampus in vivo (Data on ﬁle, Neuralstem, non-peer-reviewed).
It has shown behavioral efﬁcacy at three different doses in a
mouse model of depression (novelty suppressed feeding) after
daily oral administration for 28 days (Data on ﬁle, Neuralstem,
non-peer-reviewed). The brains of treated mice showed signiﬁcantly
increased neurogenesis in the dentate gyrus and signiﬁcantly
increased hippocampal volume (Data on ﬁle, Neuralstem,
non-peer-reviewed). NSI-189 is believed to have a highly speciﬁc effect
in the hippocampus and subventricular zone, the two well-known
neurogenic regions in adult central nervous system, and nowhere
else in the central nervous system (Data on ﬁle, Neuralstem, non-
peer-reviewed). In vitro studies with NSI-189 showed limited
metabolism involving oxidative processes combined with some
evidence for glucuronide conjugation (Data on ﬁle, Neuralstem,
non-peer-reviewed). Estimates of total clearance of NSI-189 (CL/F)
in healthy normal subjects indicated moderate clearance
approximating hepatic blood ﬂow (Data on ﬁle, Neuralstem,
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non-peer-reviewed). Urine samples from preclinical or clinical
testing have not been analyzed.
This double blind, randomized, placebo controlled,
multiple-ascending dose study with three cohorts was designed
to primarily address safety and PK objectives in MDD patients. The
primary goal of the study was to identify the maximum safe dose
of NSI-189 that could be administered for at least 28 days in MDD
patients and to determine multiple dose/steady-state PK. Second,
exploratory analyses of its effects on depressive symptoms and
quantitative electroencephalogram (qEEG) measures were con-
ducted, as well as hippocampal volumetric changes.
MATERIALS AND METHODS
This was a double blind, randomized, placebo controlled, multiple-dose
study to assess the safety and PK of NSI-189 phosphate in patients with
MDD. The study was performed in male and female patients 18–60 years of
age, inclusive, diagnosed with MDD, recurrent, as per the Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV-TR) criteria and conﬁrmed
by the Structured Clinical Interview for DSM-IV speciﬁc for Clinical Trials
(SCID-CT). Staff psychiatrists/psychologists at the MGH Clinical Trials
Network and Institute performed independent remote SAFER (state versus
trait; assessability; face validity; ecological validity; and rule of three Ps
(pervasive, persistent, and pathological)) interviews9,10 for screened
patients who the sites deemed eligible for randomization to conﬁrm
validity of the diagnosis of MDD and eligibility for the study. The study
implementation, including magnetic resonance imaging (MRI) and qEEG
assessments, and patient recruitment was conducted at the Parexel Los
Angeles Early Phase Clinical Unit. After complete description of the study
to the subjects, written informed consent was obtained by each participant.
Patients at screening were either medication free with a history of taking
antidepressant medication(s) in the past for their depressive disorder, or
were allowed to be on antidepressant medication(s). Eligible patients on
antidepressants were admitted to the unit on day − 5 to complete a
wash-out period, and were reconﬁrmed for eligibility at the baseline
assessments. Eligible patients not on antidepressant medication when
enrolled in the study were admitted to the unit on day − 2 for
reconﬁrmation of eligibility and baseline assessments.
Twenty-four patients were planned for enrollment into three dose groups
(40mg q.d., 40mg b.i.d., and 40mg t.i.d.) with eight patients per cohort.
Within each cohort (with at least three female patients), six patients were
randomized to NSI 189 phosphate and two patients were randomized to
placebo, in this double blind, randomized, placebo controlled, multiple-dose
study with three ascending cohorts (N=24) (Figure 1).
The randomization code was provided by Max Neeman International,
India, before the study. Two sets of sealed code break envelopes were
supplied. One set was kept at the Clinical Unit and the other set was sent
to the PAREXEL Pharmacovigilance reporting department. Dose escalation
by titrating from 40mg q.d. to 40mg b.i.d. and 40mg t.i.d. drug
administration was based on pre-clinical ﬁndings demonstrating central
nervous system-related adverse events in animals associated with Cmax
(Data on File, Neuralstem). Prior Phase 1 clinical studies with doses of
NSI-189 up to 80mg as a single dose demonstrated no drug-related
adverse events (Data on File, Neuralstem). Therefore, to reduce the risk of
possible peak-related adverse events, split daily dosing was used to permit
higher exposures of NSI-189 without increasing the risk of peak-related
adverse events (AEs). During the study, patients underwent a screening
visit (day − 37 to − 6), Admission and washout (day − 5 to − 1) for patients
treated with antidepressant medication(s) at screening and (day − 2 to − 1)
for patients not being treated with antidepressant medication(s) at
screening, in-house double-blind dosing (day 1 to 28), and follow up
and end-of-study visits (day 35 (±3), day 42 (±30), day 49 (±3), day 70 (±3),
day 56 (±3) and day 84 (±3) (end of study)). During the in-house dosing,
safety, PK and PD assessments took place relative to dosing. In addition to
having the study IRB approved, a Safety Monitoring Board reviewed 7-day
safety data of all patients within each dose cohort, before proceeding to
the next ascending dose cohort, according to the safety stopping criteria
outlined in the protocol. A total of eight patients were on psychotropic
Figure 1. Consort chart.
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medications requiring tapering off before randomization per protocol. A
total of six patients were restarted on psychotropic medications post
day 28. There were two patients who were initiated on different
antidepressants than the ones they originally were titrated off.
Inclusion criteria
Patients who met the following criteria were considered eligible to
participate in the study:
(1) Males and females 18–60 years of age, inclusive.
(2) Diagnosis of MDD, recurrent, as per the DSM-IV-TR criteria and
conﬁrmed by the Structured Clinical Interview-Clinical Trials. Their
major depressive episode was conﬁrmed via SAFER interview9
administered by remote, independent raters.
(3) MADRS11 score of 15–30, inclusive, at screening and baseline, conﬁrmed
via independent interview administered by remote, independent raters.
(4) The following applied to female patients only: non-pregnant,
non-lactating females of childbearing potential who agreed to use
medically acceptable forms of birth control from screening until the
end of study.
(5) The following applied to male subjects: male subjects with a female
partner of childbearing potential were required to use an effective
method of birth control or practice abstinence during this study and
for 3 months following discontinuation of study medication.
(6) Body mass index of ⩾ 19.5 and ⩽ 35.0 kg/m2 at screening. Bodyweight
must be 450 kg.
Exclusion criteria
Patients meeting one or more of the following criteria were not considered
eligible to participate:
(1) Clinically signiﬁcant history or evidence of cardiovascular, respiratory,
hepatic, renal, gastrointestinal, endocrine, neurological, immunological,
dermatological or psychiatric disorder(s), including substance abuse or
dependence, or other major disease.
(2) Clinically signiﬁcant suicidal or homicidal ideation or behavior currently
or during the preceding 6 months.
(3) Clinically signiﬁcant abnormal clinical laboratory tests or ECGs.
(4) Regular use of any tobacco product exceeding 10 cigarettes or their
equivalent within 3 months before day 1.
Efﬁcacy measures
The following measures were administered with both clinicians and
patients being blind to treatment assignment:
(1) Montgomery-Asberg Depression Rating Scale (MADRS):11 this 10-item
clinician-rated instrument measures depression severity.
(2) CGI-S and Improvement (CGI-I) Scales.12 These clinician-rated scales
rate the severity of the disorder and the global improvement as the
beginning of the study.
(3) SDQ:13 This validated self-rating instrument has 44 items on a scale of
1–6, measuring multiple depressive symptom domains.
(4) MGH CPFQ:14 this is a brief (7-item), validated self-report inventory to
assess rates of signiﬁcant cognitive symptoms such as memory,
attention and executive functioning difﬁculties.
Hippocampal and amygdala volumes
Structural MRI scans were acquired using a GE Signa, 1.5 T Excite HD MRI
(GE Medical Systems, Milwaukee, WI, USA) with a 16-channel head coil.
During scanning, the participant’s head was immobilized using tight foam
padding to minimize motion. Each participant underwent sagittal
T1-weighted, three-dimensional, non-contrast enhanced, inversion recovery
high-resolution spiral imaging (IR-SPGR) sequence, with the following
acquisition parameters: 1-mm-isotropic voxel size, inversion time 500ms,
repetition time 8.5 ms, echo time 3.75ms, ﬂip angle 10 deg and ﬁeld of
view 192× 192mm, slice thickness 1.2 mm, number of slices 170. Four
scans were obtained for each subject at baseline, day 28, 56 and 84. MRI
data were processed using the standard longitudinal processing stream in
FreeSurfer 5.3 (Massachusetts General Hospital, Boston, MA, USA).15 The
automated segmentation procedures were used to segment the left and
right hippocampal and amygdala formation for each subject at each time
point. Each subject’s scan and segmentation were visually inspected by a
trained operator to conﬁrm accuracy according to a previously published
protocol.16 No manual edits were performed. Hippocampal and amygdala
volume measurements were obtained for each subject at each time point
(in mm3). Because of technical problems with scan acquisitions, data were
not available for n=3 at day 84 (two placebo, one NSI-189).
Peripheral biomarker and pharmacokinetic assessments
Pharmacokinetics. Per protocol, plasma concentrations of NSI-189 were
collected at speciﬁed time points relative to NSI-189 dosing at day 1 up to
day 84. Blood samples for the determination of the plasma concentrations
of NSI-189 were collected before dose administration (predose) on day 1
and then throughout the 31 days, and 3 days after the last dose on day 28.
Full proﬁles were measured on day 1, after either 1, 2, or 3 doses, on day
14, and after the last dose on day 28. Samples were measured using a
validated LC/MS/MS method by WIL Research (Ashland, OH, USA).
Pharmacokinetic parameters for NSI-189 in plasma were calculated using
non-compartmental analysis using individual patient concentrations vs
time graphs using SAS for Windows (Version 9.3, SAS Institute, Cary, NC,
USA). The lower limit of quantitation for NSI-189 in human plasma was
1 ngml− 1. In this study, PK was not evaluated on fasted subjects. In the
previous, Phase 1a study, PK was done after overnight fasting and, in a
substudy, we compared PK of fasted vs fed. Food did not affect the overall
drug exposure or the Cmax (Data on File, Neuralstem). Therefore, in the
current study, PK was conducted without overnight fasting. Subjects were
dosed 1–4 h before meal and no food was provided for 2 h post dose.
Peripheral biomarkers. Each subject had a blood sample drawn at the
indicated time points ranging from − 5 to 84 days post treatment. Plasma
was stored frozen at ⩽− 70 °C until shipment to Ridge Diagnostics
(Research Triangle Park, NC, USA) for analysis. Plasma samples were tested
by immunoassay for plasma levels of 10 biomarkers (alpha-1-antitrypsin
(A1AT), apolipoprotein C3 (ApoC3), brain-derived neurotrophic factor,
cortisol, epidermal growth factor, myeloperoxidase, prolactin, resistin,
soluble tumor necrosis factor receptor type 2, and thyroid stimulating
hormone). The majority of the analytes were measured by enzyme-linked
immunosorbent assay, whereas A1AT and apolipoprotein C3 were
measured by turbidimetric assays developed by Ridge. There was no
difference in the frequency of blood draws between placebo and active
subjects. The site staff was blinded to treatment nature. However, the
peripheral biomarker analysis was carried out in frozen samples once the
study was completed and the study was unblinded. Therefore, biomarker
levels of each analyte were measured at speciﬁed intervals for each subject
from day 1 through day 84 treated with NSI-189 (n=18) for 28 days.
Biomarker levels in patients who received placebo (n= 6) were instead
measured only twice (baseline and day 28) during that time period.
Safety and qEEG. Safety EEG assessments were obtained for all cohorts at
screening visit, day 1, 14 and 28, at 1 h and 3 h post dose, bracketing the
Tmax of NSI-189 and were relative to the dosing frequency (that is, 40mg q.d.
after ﬁrst dose, every morning; 40 mg b.i.d. after 2nd dose, early evening; and
40 mg t.i.d. after the third dose of the day, after midnight). In addition safety
EEG assessments were performed at days 3 and 7 for the 40mg b.i.d. and
40mg t.i.d. cohorts only. Digital EEGs (Cadwell Laboratories, Kennewick, WA,
USA) were recorded with subjects resting with eyes closed using 19 scalp
electrodes placed according to the International 10/20 System, and including
ECG, and eye movement monitoring. Further, EEG recordings obtained at the
baseline visit and 6 h post-dose on day 14 and 28 were analyzed using power
spectral analysis. Physiological and instrumentation artifacts were identiﬁed
and removed from EEG ﬁles manually by an experienced technologist. Epochs
of cleaned EEG data are submitted to power spectral analyses using Brain
Vision Analyzer software (Brain Products, Gilching, Germany) and results were
banded over the 4–6, 6–8, 8–10 and 10–12Hz frequency ranges for each
recording electrode.
Statistical analyses
Differences across cohorts in clinical and demographic characteristics were
analyzed using χ2 test for categorical variables and analysis of variance for
continuous variables. Spontaneous adverse events were descriptively
tabulated. With respect to the exploratory analyses of efﬁcacy, the three
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cohorts were combined to increase power so that the placebo group had
six subjects, and the NSI-189 group (all doses) had 18 subjects. Analysis of
covariance was used for the following dependent variables: CGI-I, MADRS,
SDQ, CPFQ and hippocampal and amygdala volumes observed at day 28
(end of treatment) and day 84 (end of follow-up). Covariates were the
baseline values to adjust for initial differences (for CGI-I, day 7 was used as
covariate). Excluding n= 2 early termination patients (replaced) and
incomplete follow-up (that is, missing day 84) for n= 2 (not replaced).
Effect sizes were estimated using Cohen’s17 d group mean differences:
d= 0.20 (small); d=0.50 (medium); d= 0.80 (large). A post hoc analysis was
conducted on the hippocampal and amygdala volume data, as data were
missing for two out of six placebo patients at day 84. Thus, a repeated
measures analysis of variance (ANOVA) was conducted in the pooled
NSI-189 group only to test if there was a trend over time. Data analyses for
qEEG measures were based on repeated-measures analysis of variance and
Student’s t as appropriate. Logistic regressions were carried out to analyze
the peripheral biomarkers.
RESULTS
The study successfully recruited 24 MDD patients. Table 1
summarizes the clinical and demographic characteristics of the
sample. The patients assigned to placebo in the three cohorts
were numerically younger than patients assigned to active
treatment. Among the pooled active group patients (n= 18),
seven (38.9%) were Caucasian, seven (38.9%) were
African-American, three (16.7%) were Hispanic and one (5.6%)
was Asian, compared with the pooled placebo group, where four
(66.6%) were Caucasian, zero (0%) were African-American, 2
(33.3%) were Hispanic and zero (0%) were Asian. With respect to
gender, seven (38.9%) of the pooled active group patients (n= 18)
were males vs seven (83.3%) of the pooled placebo group (n= 6).
Two patients dropped out of the study post randomization, and
both were replaced. The ﬁrst patient was screened on 24 May
2012, and the ﬁrst dosing was 12 June 2012. The last subject, last
visit was on 13 November 2013 (Table 1).
With respect to the primary aim of the study, NSI-189 was well
tolerated supporting the dose escalation up to 40mg t.i.d. by the
Safety Monitoring Board. Table 2 summarizes the spontaneously
reported adverse events. Administration of 40mg doses of
NSI-189 q.d., 40 mg b.i.d. and 40mg t.i.d. for 28 days resulted in
accumulation consistent with the mean T½ of 17.4 ± 3.06,
20.5 ± 3.51 and 18.6 ± 4.14 h, respectively. Steady state was
reached after 96–120 h, consistent with the T½ and independent
of the dosing regimen. Figures 2, 3, 4 provide the pharmacokinetics
curves obtained with the study. The predicted accumulation
for the q.d. regimen was in good agreement with the observed
values based on Cmax and area under the curve (AUC) (0–τ),
whereas those for the b.i.d. and t.i.d. regimens were roughly
proportional. Day 28 AUCs (0–24) were 1144 ± 276, 2791 ± 1443
and 4384 ± 1217 h ×ngml− 1 for the q.d., b.i.d. and t.i.d. regimens,
respectively. Mean time to maximal peak concentration (Tmax)
ranged from 1–2 h at day 1 and 28. There were no obvious
pharmacokinetic differences between males and females (Table 2).
Efﬁcacy
With respect to the exploratory efﬁcacy assessments, Figure 5a
shows the results of the analyses of the SDQ. There was a
signiﬁcantly greater reduction in depressive symptoms at day 28
(the end of the double-blind phase) in the pooled NSI-189 patients
compared with the placebo-treated patients on the SDQ. The
signiﬁcant advantage of the pooled NSI-189 patients compared
with the placebo-treated patients was maintained through the
end of the follow-up period (day 84). Figures 5b and c show trends
toward signiﬁcantly greater reduction in depressive symptoms as
measured by the MADRS and the CGI-I at day 28. These trends
were maintained through the end of the follow-up period (day
84), although the differences between drug and placebo were not
statistically signiﬁcant. These treatment responses were for the
most part in patients who did not restart prior treatments, if they
were on any. For the remainder of the patients, the treatments
that were restarted were considered not or only partially effective
prestudy. Figure 5d demonstrates the signiﬁcant reduction in
symptoms on the CPFQ at day 28 in the pooled NSI-189 patients
compared with the placebo-treated patients, maintained until the
end of the follow-up period. The effect sizes detected with the
four depression outcome measures ranged from 0.57 (CGI-I) to
0.90 (SDQ), 0.94 (CPFQ), and 0.95 (MADRS), consistent with a
medium to large effect size (Figures 5a–d).
Hippocampal and amygdala volumes
Figures 6a–d describe the means over time of the hippocampal
and amygdala volumes. Analysis of covariance results did not
show signiﬁcant differences in hippocampal volume at day 28
(left: F(1,21) = 0.06, P= 0.80; right: F(1,21) = 0.71, P= 0.41) or day 84
(left: F(1,18) = 1.25, P= 0.28; right: F(1,18) = 4.17, P= 0.06) between
the pooled NSI-189 and placebo-treated patients. Results were
also non-signiﬁcant for the control site, the amygdala, at day 28
(left: F(1,21) = 4.30, P= 0.05; right: F(1,21) = 0.63, P= 0.44) or day 84
(left: F(1,18) = 0.00, P= 0.98; right: F(1,18) = 0.01, P= 0.91). The post
hoc repeated measures analysis of variance suggested a modest
but not statistically signiﬁcant increase in the left hippocampal
volume in the NSI-189-treated patients (b= 0.35, P= 0.12), but not
the right side (right: b=− 0.03, P= 0.82). In the control site, the
trend was non-signiﬁcant on the left side (b=− 0.03, P= 0.74), and
signiﬁcant on the right side (b= 0.32, P= 0.049).
Table 1. Patients’ demographics and clinical characteristics
Pooled placebo (n=6)
N (%)
40 mg q.d. (n= 6)
N (%)
40 mg b.i.d. (n= 6)
N (%)
40 mg t.i.d. (n=6)
N (%)
P
Ethnic origin, n (%)
Caucasian 4 (66.6) 3 (50.0) 2 (33.3) 2 (33.3) 0.604a
African American 0 (0.0) 2 (33.3) 3 (50.0) 2 (33.3)
Hispanic 2 (33.3) 1 (16.6) 1 (16.6) 1 (16.6)
Asian 0 (0.0) 0 (0.0) 0 (0.0) 1 (16.6)
Gender, n (%) 0.262a
Male 5 (83.3) 2 (33.3) 3 (50.0) 2 (33.3)
Female 1 (16.6) 4 (66.6) 3 (50.0) 4 (66.6)
Age (year), mean (s.d.) 28.20 (4.75) 34.00 (3.50) 38.50 (12.94) 40.50 (9.92) 0.098b
MADRS total score at screening, mean (s.d.) 25.20 (2.93) 26.00 (3.35) 26.83 (2.64) 24.83 (2.56) 0.636b
Abbreviation: ANOVA, analysis of variance. aStatistical method used, χ2 test. bStatistical method used, one-way ANOVA.
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Table 2. Adverse eventsa
Side effect Pooled placebo 40 mg q.d. 40 mg b.i.d. 40 mg t.i.d. Pooled active Pooled placebo
(n=6) N (%) (n= 6) N (%) (n=6) N (%) (n=6) N (%) (n= 18) N (%) (n= 6) N (%)
Autonomic
Dry mouth 0 (0%) 0 (0%) 2 (33.3%) 0 (0%) 2 (11.1%) –
Palpitation 0 (0%) 1 (16.7%) 0 (0%) 0 (0%) 1 (5.6%) –
CNS/psychiatric
Headache 3 (50.0%) 3 (50.0%) 3 (50.0%) 3 (50.0%) 9 (50%) 3 (50%)
Dizziness 1 (16.7%) 0 (0%) 1 (16.7%) 4 (66.7%) 5 (27.8%) 1 (16.7%)
Somnolence 1 (16.7%) 3 (50.0%) 1 (16.7%) 1 (16.7%) 5 (27.8%) 1 (16.7%)
Fatigue 0 (0%) 1 (16.7%) 0 (0%) 0 (0%) 1 (5.6%) –
Restlessness 0 (0%) 0 (0%) 0 (0%) 1 (16.7%) 1 (5.6%) –
Poor quality of sleep 0 (0%) 1 (16.7%) 0 (0%) 0 (0%) 1 (5.6%) –
Nightmare/vivid dream 0 (0%) 1 (16.7%) 1 (16.7%) 1 (16.7%) 3 (16.7%) –
Paresthesia 0 (0%) 1 (16.7%) 0 (0%) 1 (16.7%) 2 (11.1%) –
Insomnia 0 (0%) 1 (16.7%) 1 (16.7%) 1 (16.7%) 3 (16.7%) –
Irritability 0 (0%) 1 (16.7%) 0 (0%) 0 (0%) 1 (5.6%) –
Difﬁculty concentrating 1 (16.7%) 0 (0%) 0 (0%) 0 (0%) – 1 (16.7%)
Hyperthymia 1 (16.7%) 0 (0%) 0 (0%) 0 (0%) – 1 (16.7%)
Gastrointestinal
Dyspepsia 1 (16.7%) 0 (0%) 0 (0%) 0 (0%) – 1 (16.7%)
Abdominal pain 1 (16.7%) 0 (0%) 0 (0%) 0 (0%) – 1 (16.7%)
Nausea 0 (0%) 0 (0%) 0 (0%) 2 (33.3%) 2 (11.1%) –
Skin and subcutaneous tissue disorders
Skin pain 0 (0%) 1 (16.7%) 0 (0%) 0 (0%) 1 (5.6%) -
Rash 0 (0%) 0 (0%) 0 (0%) 1 (16.7%) 1 (5.6%) -
Abbreviations: AE, adverse events; CNS, central nervous system; EEG, electroencephalogram. aNumber of subjects experiencing an AE which were assessed by
the Site Investigator as possibly, probably or deﬁnitely related to study drug during the trial period. One placebo subject (#601) who was withdrawn on day 8
owing to abnormal EEG and one b.i.d. subject (#607) who withdrew consent on dy 1 for personal reasons are excluded from this table but are included in the
Supplementary Table S1.
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Figure 2. Mean± s.e. plasma concentrations of NSI-189 on days 1, 14 and 28 during oral administration of 40 mg Q24H to subjects with MDD
—linear axes (left panel) and semi-logarithmic axes (right panel). MDD, major depressive disorder.
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Figure 3. Mean± s.e. plasma concentrations of NSI-189 on days 1, 14, and 28 during oral administration of 40mg Q12H to subjects with MDD
—linear axes (left panel) and semi-logarithmic axes (right panel). MDD, major depressive disorder.
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Peripheral biomarker assessments
Plasma levels of a subset of biomarkers at baseline did partially
predict the clinical outcome after 28 days of treatment. Of the 18
active patients who completed the study, 2 were non-responders
in that their MADRS score remained within the original moderate
depression classiﬁcation (MADRS score 20–34). Twelve13 treated
patients were designated responders, deﬁned as those who had
either 50% drop in MADRS score or returned to a normal range
(MADRS score 0–6). Four (4) patients were designated partial
responders since the post-treatment MADRS score indicated a
change from moderate to mild depression. We used logistic
regression modeling of baseline biomarker data in this limited
sample to predict whether an individual patient fully or partially
responded to treatment with NSI-189. In this analysis, we used the
MADRS scores at day 28 the last treatment day. Using baseline
plasma levels of brain-derived neurotrophic factor, epidermal
growth factor, myeloperoxidase, tumor necrosis factor receptor
type 2 and A1AT, the model, with one exception (patient 608), was
able to identify the response to NSI-189, in 17 out of 18 cases that
are consistent with therapeutic effects shown by the decrement in
MADRS score. Table 3 indicates the individual patient identiﬁer,
and the response group designation (R, responder; PR, partial
responder; NR, non-responder) and the predicted probability of
response based on analysis of baseline biomarker data.
Safety and qEEG
Results of safety EEG assessments bracketing the Tmax (1–2 h) of
NSI-189 revealed no seizure activity in any case. No new EEG
ﬁndings were identiﬁed by visual inspection post dose that were
persistent in ﬁnal recordings. One subject showed sharp activity
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Figure 4. Mean± s.e. plasma concentrations of NSI-189 on days 1, 14, and 28 during oral administration of 40mg Q8H to subjects with stable
depression — linear axes (left panel) and semi-logarithmic axes (right panel). MDD, major depressive disorder.
Figure 5. (a–d) Efﬁcacy outcomes in means over time.
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that was not seen in the recording at discharge. Results of qEEG
analyses show increased high-frequency alpha with active
treatment and lower high-frequency alpha, or less change with
placebo. Figure 7 displays the topographs of high-frequency alpha
(10–12 Hz) comparing baseline with day 28. This effect is
particularly prominent in the left posterior temporal (T5; t= 2.45,
P= 0.0247) and left parietal regions (P3; t= 3.31, P= 0.004) in the
active treatment group and is similar when comparing
quantitative EEG at baseline to either day 14 or 28 assessments.
Signiﬁcant univariate effects comparing amplitude from baseline
to post-dose assessments are seen only for changes within the
active treatment group.
DISCUSSION
The primary aims of this study concerning the analyses of the
safety, tolerability and pharmacokinetics of NSI-189 were
achieved. In this Phase 1b study, NSI-189, a novel chemical entity
that stimulated neurogenesis in earlier studies, was well tolerated,
and administration of 40 mg doses of NSI-189 Q24H, Q12H and
Q8H for 28 days resulted in accumulation consistent with the
mean t½ of 17.4–20.5 h, with steady state being reached after
96–120 h, consistent with the t½ and independent of the dosing
regimen. The study also showed that NSI-189 had signiﬁcantly
greater antidepressant effects than placebo in two (SDQ and
CPFQ) of the four depression outcome measures. Although
statistical signiﬁcance was achieved only with the self-rating
scales, presumably because of the tighter s.d., the effect size
detected with the clinician-rated MADRS (0.95) was similar to the
effect sizes of the two self-rated depression outcome measures
(0.90 for the SDQ and 0.94 for the CPFQ). Plasma levels of a subset
of biomarkers at baseline did partially predict the clinical outcome
after 28 days of treatment. MRI data suggested a potential modest
increase in hippocampal volume in NSI-189-treated patients,
which would be in line with the postulated neurogenetic
mechanism underlying NSI-189 treatment, but this was not
signiﬁcant and was not different from the changes observed on
the small cohort on placebo, and are purely provided for
descriptive purposes. Also note that trends of similar magnitude
were observed in the control site, the amygdala, thereby
underscoring the possibility of a spurious ﬁnding.
The study results are consistent with the growing body of
evidence that treatment with antidepressant drugs increases
hippocampal neurogenesis and with the hypothesis that
pre-clinical neurogenesis matched with conﬁrmatory behavioral
assays may be useful as a drug discovery strategy.7,8
It is worth noting that the signiﬁcant beneﬁts on the SDQ and
the trends for improvement on the MADRS and CGI-I were
maintained steadily beyond the acute phase of the double-blind
administration and were still present at day 84, with the exception
perhaps of the 40 mg q.d. regimen. This ﬁnding is in sharp
contrast to the rapid return of symptoms typically observed
following discontinuation of standard antidepressants (with
relapse rates hovering ~ 20% on placebo 2 months after
antidepressant treatment discontinuation).18 These treatment
responses were for the most part in patients who did not restart
prior treatments, if they were on any. For the remainder of the
patients, the treatments that were restarted were considered not
or only partially effective prestudy. Biomarker changes were not
collected in the post-treatment period. If replicated in a future
study, this observation suggests the presence of unique features
of NSI-189, such as a more durable antidepressant effect.
Another interesting ﬁnding related to NSI-189 is the signiﬁcant
improvement compared with placebo in cognitive symptoms, as
measured by the CPFQ. Future studies should explore whether
such pro-cognitive effect may be all explained by the
Figure 6. The means over time of the hippocampal and amygdala volumes (a–d).
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improvement in depressive symptoms, or instead by speciﬁc
effects of the increased neurogenesis on cognition, given the
established relationship between these two.19 Exploratory
analyses of qEEG changes demonstrated signiﬁcant changes
indicating a direct inﬂuence on the nervous system, and these
changes were seen only for the active NSI-189 group. Interestingly
these ﬁndings are best seen in regions near the hippocampus, and
were more prominent on the left. Neuropsychological correlates
of these changes would be expected to include modulating
context regulation of affect.20
Preliminary analysis of a small sample set with a low ‘event per
variable’ ratio suggests that prediction of response by analyzing
peripheral biomarkers may be possible from baseline biomarker
proﬁling in plasma samples. In that regression model
brain-derived neurotrophic factor, epidermal growth factor,
myeloperoxidase, tumor necrosis factor receptor type 2 and
A1AT are key analytes.
The main limitation of the study is the small sample size (n= 24)
and the unbalanced randomization, with 24 subjects assigned to
active treatment and only 6 to placebo, although this is a design
typical of Phase 1 studies. These two issues may increase the
likelihood of false positives. In addition patients who were willing
to participate in this study agreed to an inpatient stay, which may
not be representative of patients with MDD. Despite these
limitations, each cohort seemed to have consistently shown an
antidepressant effect and the overall effect sizes were quite
robust. MDD treatment trials often have high placebo response
rates, and the opportunity for signal detection in a small early
phase study is usually quite limited.
However, this Phase 1b study included a series of
methodological innovations which may have contributed to the
success of the study. Staff psychiatrists/psychologists at the MGH
Clinical Trial Network Institute performed independent remote
SAFER interviews9 for screened patients the sites deemed eligible
for randomization to assess validity of a diagnosis of depression
and eligibility for the study. Therefore, both diagnosis and
appropriate illness severity were independently veriﬁed. This
veriﬁcation may have contributed to a relatively low placebo
response rate, as shown in previous studies of our group.21,22
Another innovation involves the use of a relatively more
comprehensive measure of depression, the self-rated SDQ, a valid
and reliable questionnaire assessing psychological, physical and
behavioral symptoms of depression.13 This instrument is more in
line with the Research Domain Criteria approach to assessment of
depressed patients23 and includes measures of irritability, anger
attacks and anxiety symptoms together with the commonly
considered symptoms of depression.
In summary, consistent with ﬁndings from our group that a
neurogenic combination therapy was more effective than placebo
in MDD,24 a novel neurogenic compound, NSI-189, has shown
promise as a potential treatment for MDD in a Phase 1B,
double-blind, randomized, placebo controlled, multiple-dose
study with three ascending cohorts.
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